Catalyst Event

Gilead Sciences Inc (GILD) · Other

From KEDI U.S. Tech100 90% Participation + Daily Options Premium Index (KUSTC100P)

5/21/2026, 12:00:00 AM

OtherSentiment: Positive

Completed the acquisition of Tubulis on 2026-05-21 to strengthen the oncology portfolio. Analysts forecast a low price impact (>=1%) as a strategic bolt-on acquisition, expected.

Korean Translation

2026-05-21 항암 포트폴리오 강화를 위해 투불리스(Tubulis) 인수를 완료함. 분석가들은 전략적 보충 인수로서 1% 이상의 주가 영향이 있을 것으로 예상됨.

Related Recent Events

View Full Timeline